Compare AbbVie Inc (ABBV) vs Cardinal Health Inc (CAH) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Cardinal Health (CAH) trades at $236.4, down 0.53% on the day, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The company reported $222.58B in revenue for 2025, with net income rising to $1.56B, and recently announced two home-care acquisitions to expand its at-Home Solutions segment. Analyst sentiment is positive, with a consensus price target of $262.80 and no sell ratings among 33 analysts.

The stock presents a favorable risk-reward profile with upside to the consensus target, supported by earnings beats and strategic growth initiatives. Key risks include high leverage with a debt-to-asset ratio of 16.09 in 2025 and thin net margins of 0.62%, which could pressure profitability if revenue growth slows or interest costs rise.